|1.||Iwata, Nakao: 5 articles (12/2014 - 01/2013)|
|2.||Takaki, Manabu: 4 articles (02/2015 - 12/2012)|
|3.||Miyamoto, Seiya: 4 articles (12/2014 - 01/2012)|
|4.||Kishi, Taro: 4 articles (12/2014 - 02/2013)|
|5.||Matsuda, Yuki: 4 articles (12/2014 - 02/2013)|
|6.||Tenjin, Tomomi: 4 articles (12/2014 - 01/2012)|
|7.||Nakamura, Hiroshi: 4 articles (04/2013 - 12/2008)|
|8.||Mizuki, Yutaka: 3 articles (02/2015 - 12/2012)|
|9.||Yamaguchi, Noboru: 3 articles (12/2014 - 01/2012)|
|10.||Miyake, Nobumi: 3 articles (12/2014 - 01/2012)|
|1.||Schizophrenia (Dementia Praecox)
12/01/2014 - "Blonanserin was well tolerated and effective for the treatment of first-episode schizophrenia in terms of subjective wellness, cognition, and a wide range of pathological symptoms. "
02/10/2003 - "These findings suggest that AD-5423 would be clinically effective against both the positive and negative symptoms of schizophrenia."
10/01/2015 - "Thus, blonanserin is useful for the treatment of Chinese schizophrenia patients. "
07/01/2010 - "These findings suggest that blonanserin is useful in the treatment of schizophrenia."
12/01/2014 - "Twenty-three antipsychotic-naïve patients with first-episode schizophrenia were treated within an open-label, 1-year, prospective trial of blonanserin (2-24 mg/day). "
06/01/2011 - "Blonanserin may be effective and safe in the treatment of delirium in the ICU."
04/01/2013 - "Blonanserin for the treatment of delirium patients at an emergency medical care center: an open-label study."
06/01/2011 - "The purpose of the present study was to provide preliminary data on the usefulness and safety of blonanserin for patients with delirium in the intensive care unit (ICU). "
06/01/2011 - "Blonanserin in the treatment of delirium."
10/01/2010 - "Case of delirium complicated with pneumonia that improved with blonanserin administration."
01/01/2010 - "Nevertheless, extrapyramidal symptoms and hyperprolactinaemia were among the most common adverse reactions associated with blonanserin in noncomparative long-term studies. "
10/01/2015 - "Therefore, while a rate of PRL rising is low to moderate, hyperprolactinemia is a considerable adverse effect in the blonanserin treatment. "
11/01/2013 - "In this study, we examined the efficacy of switching antipsychotic medications to blonanserin monotherapy in patients with chronic schizophrenia with associated hyperprolactinemia. "
10/01/2015 - "Based on our findings, we conclude that low dose blonanserin medication may be useful for schizophrenia maintenance treatment without hyperprolactinemia and a high rate of relapse. "
11/01/2013 - "Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series."
|4.||Psychomotor Agitation (Akathisia)
01/01/2010 - "The global score on the Barnes Akathisia Scale in five patients with schizophrenia treated with blonanserin rapidly decreased after fluvoxamine treatment. "
01/01/2010 - "Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases."
02/01/2013 - "While dizziness (RR = 0.47, CI = 0.23-0.93, NNH = not significant) and akathisia (RR = 0.54, CI = 0.32-0.90, NNH = 7) occurred significantly less often with blonanserin than with haloperidol, blonanserin had a 1.62 higher risk of akathisia than risperidone (CI = 1.18-2.22, NNH = 8) [corrected]. "
01/01/2010 - "We report on five cases in which monotherapy of the selective serotonin reuptake inhibitor and sigma-1 receptor agonist fluvoxamine was effective in ameliorating the akathisia of patients with schizophrenia treated with the new atypical antipsychotic drug blonanserin. "
|1.||Risperidone (Risperdal Consta)
|2.||Serotonin (5 Hydroxytryptamine)
|6.||Phencyclidine (Angel Dust)
|10.||N-Methyl-D-Aspartate Receptors (NMDA Receptors)